Mass Tort brief
Surgical Mesh and Baby Formula Bellwether Trials Heat Up Federal Dockets
Heavy verdicts and pivotal bellwether openers put immense settlement pressure on medical device and consumer health giants across federal courts.
Mass Tort
An unprecedented $88 million bellwether verdict gives 2,500 injured plaintiffs massive leverage — forcing Medtronic to reserve heavy capital or risk catastrophic trial losses.
BackgroundSurgical mesh products use synthetic materials to support damaged tissue, but absorbable coatings can degrade faster than designed. Plaintiffs argue Covidien knew the protective barrier degraded prematurely, causing the mesh to stick to internal organs and create severe complications.
- The $88 million award includes $77 million in compensatory damages and $11 million for loss of consortium, marking the largest surgical mesh verdict to date.
- Jurors determined that Covidien failed to adequately warn surgeons about the risk of premature coating breakdown and resulting tissue adhesion.
- Medtronic pledged to challenge the verdict through post-trial motions and federal appeals, citing proper regulatory clearance and product efficacy.
Mass Tort
Unfreezing discovery forces cosmetics manufacturers into aggressive witness depositions — restarting intense litigation pressure across nearly 11,800 cancer claims after settlement talks stalled.
BackgroundChemical hair relaxers use harsh compounds to break down protein bonds in curly hair for long-term straightening. Plaintiffs contend that long-term chemical exposure causes uterine cancer, ovarian cancer, and fibroids, alleging cosmetics giants failed to disclose health hazards.
- Lifting the stay allows plaintiffs' counsel to pursue internal scientific records and executive communications from major defendants like L'Oréal and Procter & Gamble.
- The consolidated multidistrict docket expanded to 11,779 active lawsuits following a fresh wave of state and federal court filings.
- The court timeline targets early 2027 for selecting the first bellwether jury trials if settlement negotiations remain deadlocked.
Mass Tort
The first federal trial against Mead Johnson will set valuation baselines for over 800 premature infant claims — forcing Reckitt toward a global settlement or years of costly court fights.
BackgroundMultidistrict litigation consolidates similar federal lawsuits before one judge to streamline pre-trial evidence gathering and test cases. Over 825 claims allege specialized infant formula causes necrotizing enterocolitis, a severe intestinal disorder in pre-term babies.
- The opening case involves a pre-term infant who suffered severe intestinal damage requiring emergency surgery, setting a high-stakes emotional baseline for the jury.
- U.S. District Judge Rebecca Pallmeyer rejected Mead Johnson's preemption argument, allowing state failure-to-warn claims to proceed to full trial.
- Defense attorneys argue federal regulations mandate high-calorie formula options, setting up a sharp dispute over product safety warnings versus medical necessity.
Mass Tort
A second catheter bellwether trial gives litigants another chance to break a legal stalemate — determining whether Becton Dickinson must fund a multi-million dollar settlement framework.
BackgroundPowerPorts are implanted vascular access devices that allow doctors to deliver medications directly into blood vessels. Over 3,700 lawsuits allege barium sulfate used in the plastic housing degrades over time, causing catheters to fracture inside patients' veins.
- Catheter fragmentation can send plastic splinters into the heart and lungs, causing blood clots, organ punctures, and life-threatening vascular infections.
- The second trial focuses sharply on failure-to-warn claims, testing whether manufacturer C.R. Bard concealed known mechanical failure rates from physicians.
- Senior U.S. District Judge David Campbell is coordinating jury selection across the 3,700-case docket to establish clear settlement benchmarks.
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
